Pre-exposure prophylaxis for infants exposed to HIV through breast feeding

BMJ (Online)

Volumn 356, Issue , 2017, Pages

  Van De Perre, Philippe ^a,b   Kankasa, Chipepo ^c   Nagot, Nicolas ^a,b   Meda, Nicolas ^d,e   Tumwine, James K ^f   Coutsoudis, Anna ^g   Tylleskär, Thorkild ^h   Coovadia, Hoosen ⁱ  

^a UMR 1058 University of Montpellier   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d CENTRE MURAZ   (Burkina Faso)

^e UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^f MAKERERE UNIVERSITY   (Uganda)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; BREAST FEEDING; CLINICAL TRIAL (TOPIC); DRUG COST; HEALTH CARE ACCESS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; INFANT CARE; MEDICATION COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PREGNANT WOMAN; SOCIAL STIGMA; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; NEWBORN; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION;

ANTI-HIV AGENTS; BREAST FEEDING; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; PRE-EXPOSURE PROPHYLAXIS;

EID: 85015206158     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j1053     Document Type: Article

References (22)

1. Grant RM, Lama JR, Anderson PL, et al. iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;356:2587-99. doi:10.1056/NEJMoa1011205 pmid:21091279
2. Molina JM, Capitant C, Spire B, et al. ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;356:2237-46. doi:10.1056/NEJMoa1506273 pmid:26624850
3. WHO. WHO technical update on pre exposure prophylaxis (PreP). February 2015. http:/ /apps.who.int/iris/bitstream/10665/153587/1/WHO-HIV-2015.4-eng.pdf
4. Price JT, Wheeler SB, Stranix-Chibanda L, et al. Cost-effectiveness of pre-exposure HIV prophylaxis during pregnancy and breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2016;356(Suppl 2):S145-53. doi:10.1097/QAI.0000000000001063 pmid: 27355502
5. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2nd ed. 2016. http://apps. who.int/iris/bitstream/10665/208825/1/9789241549684-eng.pdf
6. UNAIDS. 2016 prevention gap report. http://www.unaids.org/sites/default/files/media- asset/2016-prevention-gapreport-en.pdf
7. Mofenson LM. State of the art in prevention of mother-to-child transmission. 2nd workshop on prevention trials in infants born to HIV-positive mothers, Maputo, Mozambique, 5-7 Feb 2017
8. Maman D, Huerga H, Mukui I, et al. Most breastfeeding women with high viral load are still undiagnosed in sub Saharan Africa. Abstract 32. Conference on retroviruses and opportunistic infections, Seattle, Washington, 23-26 Feb 2015
9. Tenthani L, Haas AD, Tweya H, et al. Ministry of Health in Malawi and IeDEA Southern Africa. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS 2014;356:589-98. doi:10.1097/ QAD.0000000000000143 pmid:24468999
10. Abrams EJ, Langwenya N, Gachuhi A, et al. Impact of Option B+ on ART uptake and retention in Swaziland: a stepped-wedge trial. Abstract 34. Conference on retroviruses and opportunistic infections, Boston, MA, 22-25 Feb 2016
11. Manigart O, Crepin M, Leroy V, et al. Diminution de la Transmission Mere-Enfant Study Group. Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission. J Infect Dis 2004;356:1422-8. doi:10.1086/ 424569 pmid:15378434
12. Van de Perre P, Rubbo PA, Viljoen J, et al. HIV-1 reservoirs in breast milk and translational challenges to elimination of breast-feeding transmission of HIV-1. Sci Transl Med 2012;356:143sr3. doi:10.1126/scitranslmed.3003327 pmid:22814853
13. Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L. Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models. Sex Transm Infect 2012;356(Suppl 2):i44-51. doi:10. 1136/sextrans-2012-050709 pmid:23172345
14. WHO, UNICEF. Guideline updates on HIV and infant feeding. 2016 http://apps.who.int/ iris/bitstream/10665/246260/1/9789241549707-eng.pdf
15. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;356:1173-80. doi:10.1056/ NEJM199411033311801 pmid:7935654
16. Kilewo C, Karlsson K, Massawe A, et al. Mitra Study Team. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008;356:315-23. doi:10.1097/QAI.0b013e31816e395c pmid:18344879
17. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008;356:119-29. doi:10.1056/ NEJMoa0801941 pmid:18525035
18. Coovadia HM, Brown ER, Fowler MG, et al. HPTN 046 protocol team. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012;356:221-8. doi:10.1016/S0140-6736( 11)61653-X pmid:22196945
19. Nagot N, Kankasa C, Tumwine JK, et al. ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet 2016;356:566-73. doi:10.1016/S0140-6736(15)00984-8 pmid:26603917
20. Foissac F, Blume J, Tréluyer JM, et al. ANRS 12174 Trial Group. Are prophylactic and therapeutic target concentrations different? The case of lopinavir/ritonavir or lamivudine administered to infants for the prevention of mother-to-child HIV-1 transmission during breastfeeding. Antimicrob Agents Chemother 2017;356:e01869-16.pmid:27895016
21. Shapiro RL, Rossi S, Ogwu A, et al. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther 2013;356:585-90. doi:10.3851/IMP2474 pmid:23183881
22. Smith JA, Anderson SJ, Harris KL, et al. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: A modelling study. Lancet HIV 2016;356:e289-96. doi:10.1016/S2352-3018(16)30036-4 pmid:27365203